A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Clinical trial NCT01369329 · COMPLETED

Trial details

NCT number: NCT01369329
Sponsor: Janssen Research & Development, LLC
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Crohn's Disease IBD Colitis Inflammatory Bowel Disease

Start date: 2011-07-01
Primary completion: 2013-06-01
Enrollment: 769

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.